Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20458913 | 0.93 | CHRNB2 (0.45) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27538736 | 0.88 | ADRB1 (0.39) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Pyridine SCHEMBL27687558 | 0.88 | PLD1 (0.47) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3349858 | 0.80 | ALDH1A1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL761104 | 0.80 | — | — | |
| SCHEMBL4607483 | 0.78 | ALDH1A1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL28990876 | 0.77 | PLD1 (0.41) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL28143517 | 0.77 | PRKDC (0.53) | KDM4EALDH1A1 | |
| SCHEMBL21047591 | 0.73 | PRKDC (0.40) | KDM4EALDH1A1 | |
| SCHEMBL31373496 | 0.72 | ADRA1A (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164495-B | Covalent targeting of E3 ligases | 加利福尼亚大学董事会 | 2025-04-22 | — | — | CN | disclosed |
| CN-113164495-A | Covalent targeting of E3 ligase | 加利福尼亚大学董事会 | 2021-07-23 | — | — | CN | disclosed |
| CN-107286166-B | Substituted 1,3,4, 5-tetrahydro-6H-pyrrolo [4,3,2-EF ] [2] benzazepin-6-one derivatives | 上海勋和医药科技有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-106699670-B | Benzimidazolyl piperazine compounds and its preparation method and pharmaceutical composition | 沈阳海王生物技术有限公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-106420754-B | The purposes of benzo five-membered Azacyclyl bridged piperazine derivatives | 沈阳海王生物技术有限公司 | 2019-11-05 | — | — | CN | disclosed |
| CN-103833658-B | BTA base piperazine compounds and its preparation method and pharmaceutical composition | 沈阳海王生物技术有限公司 | 2018-03-20 | — | — | CN | disclosed |
| CN-103833643-B | Benzimidazolyl piperazine compound and preparation method and pharmaceutical composition thereof | 沈阳海王生物技术有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-9802929-B2 | Benzo five-membered nitrogen heterocyclic piperidine or piperazine derivatives and preparation methods and pharmaceutical compositions thereof | SHENYANG HAIWANG BIOTECHNOLOGY CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| CN-106699670-A | Benzimidazolyl piperazine compounds, preparation method thereof and pharmaceutical composition | 辽宁艾美生物医药产业有限公司 | 2017-05-24 | — | — | CN | disclosed |
| CN-106420754-A | Use of benzo five-membered nitrogen-containing heterocyclic piperazine derivative | 辽宁艾美生物医药产业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-1861407-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007118149-A2 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL LOLLEGE (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2007-08-02 | — | — | US | disclosed |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | AVANIR PHARMACEUTICALS | 2006-10-12 | — | — | US | disclosed |
| WO-2006102191-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | AVANIR PHARMACEUTICALS (US) | 2006-09-28 | — | — | WO | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4647684-A | Process for the production of 4-amino-6,7-dimethoxy-2-[4-(furo-2-yl)-piperazin-1-yl]-quinazoline and physiologically compatible salts thereof | LUDWIG HEUMANN & CO. GMBH (DE) | 1987-03-03 | — | — | US | disclosed |
| EP-0146642-A1 | Process for the preparation of 4-amino-6,7-dimethoxy-2-(4-(furoyl-2)-piperazin-1-yl)-quinazoline and its physiologically acceptable salt | LUDWIG HEUMANN & CO GMBH (DE) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179149-A1 | THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | MIF, MMP12, MSR1 | ADRB1 1040/4885HTR3E 3127/4885HTR3B 3244/4885 |
| US-20060229314-A1 | Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors | MIF, MMP12, MSR1 | ADRB1 1040/4885HTR3E 3127/4885HTR3B 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.